The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The rates of pain free (30% frovatriptan vs. 32% almotriptan) and pain relief (54% vs. 56%) episodes at 2 h did not significantly differ between treatments. This was the case also at 4 h (pain free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent episodes were significantly (P < 0.05) less frequent under frovatriptan (30% vs. 44%), also for the attacks treated within 30 min. No significant differences were observed in sustained pain free episodes (21% vs. 18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.
|Data di pubblicazione:||gen-2011|
|Titolo:||A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine|
|Autori:||Bartolini, M; Giamberardino, MA; Lisotto, C; Martelletti, P; Moscato, D; Ganascia, B; Savi, L; Pini, LA; Sances, G; Santoro, P; Zanchin, G; Omboni, S; Ferrari, MD; Brighina, F; Fierro, B|
|Tipologia:||Articolo su rivista|
|Citazione:||Bartolini, M., Giamberardino, M.A., Lisotto, C., Martelletti, P., Moscato, D., Ganascia, B., et al. (2011). A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. THE JOURNAL OF HEADACHE AND PAIN, 12.|
|Tipo:||Articolo in rivista|
|Appare nelle tipologie:||01 - Articolo su rivista|